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Abstract
Objective
The aim of this study was to evaluate the impact of fecal donor-unrelated donor mix (FMT-
FURM) transplantation as first-line therapy for C. difficile infection (CDI) in intestinal
microbiome.
Methods
We designed an open, two-arm pilot study with oral vancomycin (250mg every 6 h for 10–14
days) or FMT-FURM as treatments for the first CDI episode in hospitalized adult patients in
Hospital Universitario “Dr. Jose Eleuterio Gonzalez”. Patients were randomized by a closed
envelope method in a 1: 1 ratio to either oral vancomycin or FMT-FURM. CDI resolution was
considered when there was a reduction on the Bristol scale of at least 2 points, a reduction
of at least 50% in the number of bowel movements, absence of fever, and resolution of
abdominal pain (at least two criteria).
From each patient, a fecal sample was obtained at days 0, 3, and 7 after treatment. Spec-
imens were cultured to isolate C. difficile, and isolates were characterized by PCR. Suscep-
tibility testing of isolates was performed using the agar dilution method. Fecal samples and
FMT-FURM were analyzed by 16S rRNA sequencing.
Results
We included 19 patients; 10 in the vancomycin arm and 9 in the FMT-FURM arm. However,
one of the patients in the vancomycin arm and two patients in the FMT-FURM arm were
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eliminated. Symptoms resolved in 8/9 patients (88.9%) in the vancomycin group, while
symptoms resolved in 4/7 patients (57.1%) after the first FMT-FURM dose (P = 0.26) and in
5/7 patients (71.4%) after the second dose (P = 0.55). During the study, no adverse effects
attributable to FMT-FURM were observed in patients.
Twelve isolates were recovered, most isolates carried tcdB, tcdA, cdtA, and cdtB, with an
18-bp deletion in tcdC. All isolates were resistant to ciprofloxacin and moxifloxacin but sus-
ceptible to metronidazole, linezolid, fidaxomicin, and tetracycline. In the FMT-FURM group,
the bacterial composition was dominated by Firmicutes, Bacteroidetes, and Proteobacteria
at all-time points and the microbiota were remarkably stable over time. The vancomycin
group showed a very different pattern of the microbial composition when comparing to the
FMT-FURM group over time.
Conclusion
The results of this preliminary study showed that FMT-FURM for initial CDI is associated
with specific bacterial communities that do not resemble the donors’ sample.
Introduction
Clostridium difficile is the causative agent of C. difficile infection (CDI) and accounts for 15–
25% of all nosocomial diarrhea cases, with an incidence of 10.4 cases per 1,000 hospital admis-
sions [1, 2]. It is estimated that CDI is responsible for almost half a million infections per year
in the United States with an estimated number of deaths of about 30,000 [3]. Hospital-acquired
CDI increases the absolute risk of in-hospital mortality over 10% [4].
According to the most recent guidelines [5], the standard treatment for the first episode of
CDI or first recurrence of mild or moderate CDI is metronidazole. Severe CDI should be treated
with intravenous (IV) metronidazole plus enteral vancomycin [5]. Even though treatment for
CDI with oral vancomycin and/or metronidazole is recommended, this approach is associated
with a significant therapeutic failure, with reported recurrences up to 30–40% of patients with
the first episode and 60% of patients with repeated recurrences[6]. Furthermore, the emergence
of the C. difficile strain NAP1/BI/027 has been associated with more failed treatments[7].
Fecal microbiota transplantation (FMT) represents a therapeutic modality with faster
reconstitution of the microbial communities of the colon. It has been used for the treatment of
patients with recurrent CDI with an efficacy of 87–91%, even in immunosuppressed patients
[8]. FMT has shown to be a safer and more effective treatment than a prolonged vancomycin
regimen in recurrent CDI cases, with clinical efficacies of 90% vs. 26% in one study [9] and
94% vs. 23% in another study [10]. To date, there are no reports on the use of FMT as initial
treatment for CDI in hospitalized patients.
The aim of this study was to evaluate the impact of FMT-FURM as first-line therapy of C.
difficile infection in intestinal microbiome.
Material and methods
Informed consent
The study was reviewed and approved by the Local Ethics Committee of the School of Medi-
cine of the Universidad Auto´noma de Nuevo Leo´n (Approval IF14-005). All study partici-
pants, or their legal guardian, provided informed written consent before study enrollment. We
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began recruiting patients once our local ethics committee authorized the research protocol
(approved on November 6th, 2014). The registry in Clinical trials was performed after the
beginning of the protocol.
All ongoing and related trials for this intervention are registered with the ClinicalTrials.gov
Identifier: NCT03107169; https://clinicaltrials.gov/ct2/show/NCT03107169?term=camacho
+ortiz&rank=1.
Design of the study, setting and inclusion criteria
We designed an open, per-protocol, two-arm pilot trial using oral vancomycin (250mg every 6
h for 10–14 days) or FMT-FURM as an alternative treatment for the first CDI episode among
hospitalized patients. Patients were included in the study from February 2015 to October 2015
in Hospital Universitario “Dr. Jose Eleuterio Gonzalez” in Monterrey, Mexico; a 450-bed
teaching hospital with an average of 22,000 annual discharges. Patients’ cases were reviewed
and evaluated by the study investigators and research coordinators. Adult patients, i.e., over 18
years old, who had been hospitalized for any cause and diagnosed with a first CDI episode
>48 h after admission were included. None of the patients had a history of CDI or had
received prior treatment for the current CDI episode. CDI cases were defined as follows: > 3
bowel movements during the prior 24 h, a Bristol scale > 5, positive test results for C. difficile
toxins A/B detected by either immunoassay (Meridian immunocard C. difficile toxins A/B) or
real-time PCR (Cepheid Xpert C. difficile/Epi, Cepheid, Sunnyvale CA) in accordance with the
manufacturers´ instructions. Patients with a toxic megacolon, suspected or documented intes-
tinal perforation, pregnancy, or the concomitant presence of colon neoplasms were excluded.
Randomization and study groups
In this pilot study, we proposed a sample size of 9 patients in each group [Power (1-beta) 80%;
Significance level (alpha) 5%; Non-inferiority limit, d value 48%. Patients were randomized by
a closed envelope method generated by the research coordinator in a 1:1 ratio to either oral
vancomycin (250 mg every 6 h for 10–14 days) or a FMT-FURM via a nasojejunal tube, supe-
rior endoscopy, or colonoscopy.
The decision on the modality of delivery of FMT-FURM was made in coordination with
the attending physician and gastroenterology team and considered the patient’s characteristics
and planned procedures.
Allocation only occurred once the study investigators received an order to administer treat-
ment from the coordinator. A patient ID was assigned to each participant and samples col-
lected were identified with this ID (no details of the study group were included in the ID).
Samples were sent to the laboratory.
Randomized patients received treatment during the study period according to the interven-
tion they were allocated. Laboratory investigators were blinded to treatment allocation.
Definitions
CDI resolution was considered when at least 2 of the following criteria were met: a) a reduc-
tion on the Bristol scale of at least 2 points, b) a reduction of at least 50% in the number of
bowel movements during the first 72 h after the FMT-FURM, c) absence of fever, and d) reso-
lution of abdominal pain. For patients with initial leukocytosis, normalization of values was
considered. Treatment was considered to have failed when3 of the resolution criteria were
not met within 72 h. Fecal microbiota re-transplantation was performed by administering a
second dose of FMT-FURM within 72 h of the first FMT-FURM.
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Selection of feces donors
Potential donors of either sex were over 18 years old, non-pregnant, with a body mass index of
20–25 kg/m2, with a normal total blood count and normal serum levels of liver enzymes, as
well as a medical history without any of the following: consumption of proton-pump inhibi-
tors, antibiotics, immunosuppressive medication, hospitalization, and diarrhea three months
prior to donation. Additional exclusion criteria were: high-risk sexual behavior, a first-degree
relative with diabetes mellitus, abdominal surgery, and any gastrointestinal disease or cancer.
Furthermore, potential donors were excluded if they tested positive for any of the following
pathogens: hepatitis A virus, hepatitis B virus, hepatitis C virus, human immunodeficiency
virus 1–2, Trypanosoma cruzi, Brucella sp., Treponema pallidum, cytomegalovirus, Epstein-
Barr virus, parasites, enteropathogenic bacteria, and rotavirus. A potential donor with a posi-
tive test for any of these pathogens was excluded from the study. Feces donors were not
requested to be on a specified diet before the donation.
Preparation of pooled fecal microbiota samples and storage
From each donor, three stool samples were collected within 2 weeks after the evaluation of the
donor. Feces from all donors were pooled, mixed, resuspended in 0.9% saline, and filtered to
remove particles > 330 μm. Glycerol, at a final concentration of 15% (v/v), was added as a bac-
terial cryoprotectant before the mixture was stored in 45-mL aliquots at -80˚C. Before use, a
45-ml -aliquot was thawed within 60 minutes by immersion in water at 30˚C and adminis-
trated to the patient. A 45-ml aliquot was considered a doses.
Patient variables, follow-up, and re-transplantation
Patient variables that were monitored after CDI diagnosis and enrollment included: frequency
of bowel movements, stool consistency, gastrointestinal symptoms, fever, and the use of antibi-
otics due to other pathologies. Additional variables that were registered were the use of proton
pump inhibitors, a previous stay at the intensive care unit, prior orotracheal intubation, immu-
nosuppression or renal replacement therapy, 30-day mortality, and attributable mortality. At
baseline and 24 h, 48 h, and 72 h after treatment, ATLAS, APACHE II, and SOFA scales were
determined. Patients in either arm without clinical improvement at 72 h after the first treat-
ment received a second treatment which was a FMT-FURM in all cases. Data monitoring and
calculations were carried with the moment of second treatment as the reference time point.
Follow-up of patients comprised from the beginning of the study in February 2015 to February
2016. The study was ended when the minimum number of patients for each arm was
completed.
Culture, genotyping, and drug susceptibility of C. difficile
Besides clinical trial, feces samples were cultured to recover and to characterize isolates. Feces
samples from patients, collected on days 0 (pre-treatment), 3, and 7 after treatment, received a
3-hour ethanol shock before inoculation onto cycloserine-cefoxitin fructose agar (CCFA).
Plates were incubated in an anaerobic chamber at 37˚C for 48 h. Colonies were identified with
both a matrix-assisted laser desorption ionization time-of-flight (MALDI-TOF) mass spec-
trometer (Bru¨ker Daltonik) and triose phosphate isomerase (tpi) genotyping by polymerase
chain reaction (PCR) [11]. Hereto, five C. difficile colonies were resuspended in 200 μL 100
mM Tris-HCl, lysed by adding 150 μg lysozyme, and incubated at 37˚C overnight. Genomic
DNA was extracted with a standard phenol-chloroform-isoamyl alcohol protocol. The genes
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tcdA, tcdB, cdtA, and cdtB were amplified using a multiplex PCR as described [12]. For tcdC
internal in-frame deletion analysis, PCR was performed as described by Persson et al. [12].
The MICs of ciprofloxacin, moxifloxacin, erythromycin, clindamycin, vancomycin, metro-
nidazole, linezolid, fidaxomicin, and tetracycline against C. difficile isolates were determined
by the agar dilution method [13]. Briefly, bacteria were cultured anaerobically in Schaedler’s
anaerobic broth (Oxoid, Basingstoke, UK) at 37˚C for 48 h, and were multipoint inoculated
(104 colony-forming units (CFU)/spot) onto Wilkins–Chalgren agar (Oxoid) containing
2-fold serial dilutions of each antibiotic (0.03–512 mg/L).
Previously reported breakpoints were considered for ciprofloxacin [14], linezolid [15], and
rifampicin [16]. Vancomycin breakpoints were those from the EUCAST Clinical Breakpoint
Tables v. 6.0, 2016, and the breakpoints of the other antimicrobials were obtained from the
clinical CLSI guideline M100-S26 [17].
Microbiota analysis
Stool samples obtained at days 0, 3 and 7 were analyzed using 16S rRNA sequencing. The sam-
ple from the donors’ pool (one sample only) was also analyzed as a reference for changes in the
FMT-FURM group.
The semi-conserved V4 region of the16S rRNA gene was amplified with primers recom-
mended by the Earth Microbiome Project [18]. The PCR amplicons were sequenced on a
MiSeq instrument (Illumina) at Molecular Research LP (Shallowater, Texas, USA) according
to the manufacturer’s instructions. Full.fasta and full.qual files provided by MRDNA (these
files contain joined reads ranging from >300 to<570 bp) were used. Demultiplexing (i.e.,
assignment of 16S rRNA reads to samples) and quality filtering were performed using default
parameters in the split_libraries_fastq.py script in QIIME 1.8. Operational taxonomic units
(OTUs) were defined using an open-reference algorithm [19] that not necessarily discarded
sequences that were not present in the reference sequence file GreenGenes 13.5 [20].
Several diversity analyses were performed using both the OTU table, generated in the previ-
ous step and the core_diversity_analyses.py script in QIIME, with minor modifications. More
importantly, we removed very low abundant OTUs (i.e., OTUs with<0.005% sequences) to
increase the sensitivity of detecting true phyla [21]. Also, the original OTU table was filtered to
allow independent analysis of both FMT-FURM and vancomycin groups. All 16S data and
associated metadata were uploaded into the Sequence Read Archive at the NCBI (BioProject
ID: PRJNA414451).
Statistical analysis
Baseline clinical and demographic characteristics were analyzed using χ2 test for categorical
data and Students´ t-test or Mann-Whitney test depending upon the distribution of the data.
Bacterial abundance was expressed as a relative proportion (i.e., percentage) and analyzed
using linear discriminative analysis (LDA) effect size (LEfSe) [22] within each treatment
group. The default LDA score of 2 and P value of 0.05 was used for the Kruskal-Wallis test.
Taxa that were identified by LEfSe to be associated with a given time point were further com-
pared using pairwise Mann-Whitney with Bonferroni correction using Paleontological Statis-
tics Software (PAST) [23]. Alpha diversity metrics included the number of OTUs (species
richness), the PD whole tree and Shannon diversity indexes, and the Chao1 metric. The Krus-
kal-Wallis was used in a PAST environment to compare the groups[24]. Beta diversity was
analyzed using both unweighted[25] and weighted[26] UniFrac distances in PAST [23].
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A principal coordinate analysis (PCoA) was used to analyze the clustering of microbial
communities using the Unifrac distances. The Adonis and ANOSIM tests were used to explore
significant clustering of communities according to a time point in QIIME.
Results
Donor and study population
Twenty-one donors were interviewed, but only 3 (mean age, 23.7 years) fulfilled all inclusion
criteria and were enrolled (Table 1). In total, 881.62 g of feces were collected. The final suspen-
sion had a concentration of 0.19 g/mL.
We included 19 patients; 10 in the vancomycin arm and 9 in the FMT-FURM arm. One of
the patients in the vancomycin arm was removed from the protocol at the request of the treat-
ing physician. Two patients in the FMT-FURM arm were eliminated from the study; one died
during the study because of an unrelated cause and the other one received oral metronidazole
due to human error (Fig 1). Demographic and main clinical characteristics of the patients are
presented in Table 2: nine patients in the vancomycin group (mean age: 46.7 ± 15.8 years,
range: 19–70 years; female, n = 3) and 7 in the FMT-FURM group (mean age: 39.7 ± 24.8
years, range: 18–91 years; female, n = 3).
FMT-FURM was administered by upper endoscopy in all but 2 cases, who received the
FMT by a nasojejunal tube that had already been installed (n = 1) or by colonoscopy in a case
with anatomical abnormalities due to head and neck neoplasia (n = 1).
Clinical data
Regarding the clinical characteristics of the patients, leukocyte counts were higher in the van-
comycin group than in the FMT-FURM group (P = 0.04). All other variables regarding clinical
and laboratory data previous to CDI, at diagnosis or outcome, did not show statistical differ-
ences between the 2 groups (Table 3). It is important to underline that this study is far under-
powered and should be considered as a pilot study.
Symptoms resolved in 8/9 patients (88.9%) in the vancomycin group, in 4/7 (57.1%)
patients the FMT-FURM group after the first FMT-FURM (P = 0.26), and in 5/7 (71.4%)
patients after the second FMT-FURM treatment (P = 0.55) (Fig 2).
Table 1. Demographic and laboratory characteristics of feces donors.
Donor 1 Donor 2 Donor 3 Average
Gender Male Female Female
Age (years) 20 27 24 23.67
Body mass index (kg/m2) 24.09 24.12 20.26 22.82
Hemoglobin (g/dL) 17.8 15 13.8 15.53
Leukocytes (103/μL) 7.7 6.9 4.6 6.40
Platelets (103/μL) 266 375 252 297
Glucose (mg/dL) 83 87 88 86
Creatinine (mg/dL) 0.8 0.7 0.6 0.7
Albumin (g/dL) 4.5 4.0 4.5 4.33
Alanine amino transferase (UI/L) 19 17 20 18.67
Aspartate amino transferase (UI/L) 19 10 11 13.33
Total bilirubin (mg/dL) 1.7 0.7 0.9 1.1
Cholesterol (mg/dL) 171 190 74 145
Triglycerides (mg/dL) 72 46 57 58.33
https://doi.org/10.1371/journal.pone.0189768.t001
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Genotypes
We recovered 12 clinical isolates, 7 from day-0 and 5 from day-3 samples (Table 4). Most iso-
lates from day 0, 6/7 (85.7%), carried genes encoding enterotoxin, cytotoxin, and the binary
toxins (tcdB, tcdA, cdtA, and cdtB), and these strains carried the putative negative regulatory
gene tcdC, with an 18-bp deletion (NAP1/027). In specimens from day 3, 4/5 (80%) were
NAP1/027.
In five cases, feces samples from both day 0 and 3 yielded positive cultures, with 4 of them
being NAP1/027. In four cases, only the day-0 (but not the day-3) sample produced a positive
culture which was NAP1/027 in all cases. In 7 other cases, samples from both days yielded a
negative culture result (Table 4).
All isolates were resistant to ciprofloxacin and moxifloxacin but susceptible to metronida-
zole, linezolid, fidaxomicin, and tetracycline. Except for 1 cases, (day-0 and day-3 samples
from patient 10, FMT group), drug susceptibility did not differ between isolates of days 0
and 3.
Fig 1. Flowchart of the study design.
https://doi.org/10.1371/journal.pone.0189768.g001
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A patient that failed to recover from infection in the vancomycin group, (patient 14) had a
C. difficile isolate that was vancomycin-resistant (MIC = 4).
16S rRNA analysis
For 16S rRNA analysis, at least 2 samples (days 0 and 3) were included from 14 patients; from
8 of them, a third sample was obtained (day 7), so that a total of 36 specimens were evaluated.
Two patients were not included in the analysis as there was only 1 sample/case.
A total of 8,369,804 raw16S rRNA sequences were generated from 37 samples (36 case sam-
ples + 1 samples from the donor pool) with the MiSeq instrument. After demultiplexing and
quality filtering, 7,169,921 good-quality 16S rRNA sequences (lowest: 63,458, highest: 294,094)
were available for OTU picking, taxonomic assignments, and further diversity analysis. The
removal of low abundant OTUs with an open reference algorithm [19] yielded a total of 803
OTUs. Diversity analyses were performed using a rarefaction of 50,000 (lowest number of
sequences per sample).
Metagenomic analysis across groups
Firmicutes, Bacteroidetes, and Proteobacteria were the most abundant phyla, comprising
~90% of all bacteria in the samples. Interestingly, Firmicutes were by far the most abundant
phylum in the donors’ pool (88%); by contrast, only 2/36 patient samples had a similar (87.4%)
or higher (98.6%) relative abundance of Firmicutes. Besides, the donors’ pool had a partially
low relative abundance of Proteobacteria as only four samples had low Proteobacteria relative
Table 2. Demographic and main clinical characteristics of patients in vancomycin and FMT-FURM groups.
Reg
Patient
Age
(years)
Gender LOS after
CID
(days)
Comorbidities Systemic
antibiotic
Outcome 30 day-
mortality
CDI attributable
mortality
Vancomycin group
1 70 F 8 CKD, DM2 No Resolved No No
2 53 M 19 PO abdominal abscess Yes Resolved No No
4 19 F 6 SLE, CKD Yes Resolved yes No
11 58 M 10 Hemorrhagic CVD No Resolved No No
12 60 M 6 Hemorrhagic CVD Yes Resolved Yes No
13 34 F 4 PO hysterectomy No Resolved No No
14 45 M 5 Pulmonary TB Yes Fail Yes Yes
15 33 M 4 Complicated pleural effusion Yes Resolved Yes No
8 48 M 6 Child B liver disease No Resolved No No
FMT-FURM
3 39 M 29 Abscessed squamous cell
cancer
Yes Fail Yes Yes
5 18 M 36 CKD, HD Yes Fail No No
6 18 F 9 SLE Yes Resolved No No
7 30 F 9 CKD, HD Yes Resolved No No
9 91 F 6 Stevens-Johnson Syndrome No Resolved No No
10 39 M 14 Thrombocytosis’ essential No Resolved No No
16 43 M 7 Meningeal TB Yes Resolved Yes No
Ca, carcinoma; CKD, chronic kidney disease; CVD, cerebrovascular disease; DM2, type 2 diabetes; FMT, transplantation of fecal microbiota; HD,
hemodialysis; LOS, length of stay; PO, postoperative; SLE, systemic lupus erythematosus; TB, tuberculosis; V, vancomycin.
https://doi.org/10.1371/journal.pone.0189768.t002
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abundance. The donor´s pool also had relatively few Bacteroidetes, as only six samples con-
tained lower relative abundances of Bacteroidetes (Fig 3).
In the FMT-FURM group, the bacterial composition was dominated by Firmicutes, Bacter-
oidetes, and Proteobacteria at all-time points (day 0, 3 and 7) and the microbiota were remark-
ably stable over time (Fig 4).
Despite the predominance of Firmicutes in the donors’ pool (88%), the proportion of Fir-
micutes in the FMT-FURM group remained relatively small and, in fact, decreased over time.
In this study, Firmicutes were mostly related to Lactobacillales and Clostridiales, bacterial
orders mainly containing organisms known to be beneficial to gut homeostasis (Fig 5).
There was no statistically significant difference in Firmicutes or any other bacterial group
within this important phylum among the three-time points.
The vancomycin group showed a very different pattern of the microbial composition when
comparing to the FMT-FURM group over time (Fig 4). For example, Bacteroidetes decreased
from an average of 29% (day 0) to 15% on day 3, and then near 0% on day 7; mostly Bacteroides
spp. were affected. By contrast, Proteobacteria increased from as little as 13% (day 0) to 47%
on day 7, and the increase was mostly due to members of Enterobacteriaceae (Fig 5). However,
no taxon displayed significant differences among the three-time points. The lack of significant
difference in microbiota composition among the three-time points was also observed
Table 3. Clinical and demographic data of patients in the vancomycin and FMT-FURM groups.
Vancomycin (n = 9) FMT-FURM (n = 7) P
Male n (%) 6 (66.7) 4 (57.1) 0.69
Mean age (years ±SD) 46.7 ± 15.8 39.7 ± 24.8 0.50
Previous to CDI
Endotracheal intubation, n (%) 1 (11.1) 4 (57.1) 0.10
ICU stay, n (%) 1 (11.1) 2 (28.6) 0.55
Hemodialysis or peritoneal dialysis, n (%) 1 (11.1) 2 (28.6) 0.55
At diagnosis
Charlson score 1.6 ± 1.7 2.4 ± 2.6 0.43
ATLAS score 6.0 ± 1.9 4.9 ± 1.7 0.22
APACHE II 11.00 ± 5.52 11.71 ± 6.29 0.81
SOFA score 11.00 ± 5.52 10.00 ± 4.36 0.70
Concomitant pharmacotherapy, n (%) 5 (55.6) 5 (71.4) 0.63
Immunosuppression, n (%) 2 (22.2) 2 (28.6) 0.77
Proton pump inhibitors use, n (%) 5 (55.6) 6 (85.7) 0.30
Temperature38˚C, n (%) 4 (44.4) 5 (71.4) 0.35
Abdominal pain, n (%) 6 (66.7) 5 (71.4) 1.00
Leukocytes (103/μL) (mean ±SD) 23.3 ± 12.0 12.9 ±6.9 0.04
Albumin (mean ± SD) 2.1 ± 0.6 2.3 ±0.8 0.55
Outcome
30-day mortality, n (%) 4 (44.4) 2 (28.6) 0.63
Attributable mortality, n (%) 1 (11.1) 1 (14.3) 0.84
Treatment failure, n (%) 1 (11.1) 2/7 (28.5) 0.06
Change in bowel movements/day (mean ±SD) 22.1 ± 88.2 12.6 ± 37.7 0.79
Change in ATLAS score (mean ±SD) 15.9 ± 34.8 26.4 ±31.9 0.54
Change in SOFA score (mean ±SD) 12.51 ± 31.2 -0.4 ± 50 0.53
Change in APACHE (mean ±SD) 12.5 ± 31.2 7.0 ± 50.4 0.79
ICU: Intensive care, APACHE II Acute physiology and chronic health evaluation, SOFA sequential organ failure assessment.
https://doi.org/10.1371/journal.pone.0189768.t003
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individually in the three patients that had complete sample sets (Fig 4). In the vancomycin
group, Firmicutes, mostly Clostridiales and Lactobacillales, remained relatively high (~50%)
and stable over time (Fig 5).
Diversity analysis
In the vancomycin group, a pattern in the number of species (i.e., OTUs at 97% similarity)
over time was observed. On average, the first sample had the highest and the last sample the
lowest numbers of OTUs (Fig 6).
However, this pattern did not reach statistical significance (Table 5). Despite the lack of sta-
tistical significance, all alpha diversity metrics tended to decrease over time in the vancomycin
group; a pattern that was not observed in the FMT-FURM group. A PCoA of both weighted
and unweighted UniFrac distances revealed no clear separation among the three-time points
(Fig 7), suggesting that the microbial communities remained stable over time despite the dif-
ferences in bacterial composition and diversity.
The FMT-FURM group showed a very a similar number of species (Fig 6) and other alpha
diversity metrics, except for Chao1 metrics (Table 5), among all three-time points (days 0, 3,
and 7). A PCoA of both weighted and unweighted UniFrac distances revealed no separation
among the 3-time points (P> 0.1 in both Adonis and ANOSIM tests) (Fig 7), suggesting that
the microbial communities were not significantly different over time.
Fig 2. Resolution rates (%) of initial C. difficile infection in patients treated with vancomycin and fecal microbiota
transplantation (FMT).
https://doi.org/10.1371/journal.pone.0189768.g002
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Discussion
In this exploratory study, we aimed to evaluate the impact of FMT-FURM as first-line therapy
of C. difficile infection in intestinal microbiome.
Most FMTs are performed with fresh feces from a related donor, but it has been proven
that frozen feces can be used for FMT [1]. Feces specimens should be frozen with glycerol to
ensure the viability of the microbiota. Freezing of feces allows reducing the time needed for
transplant to be ready and reduces the risk of involving a donor that meets the minimum
requirements and the transmission of infectious diseases through FMT. In our study, we used
frozen feces to reduce the risk of potential FMT-related infections and to increase the availabil-
ity of the FMT for critically ill patients.
We obtained from each donor three stool samples that were screened for the presence of
virus, bacteria or parasite pathogens. The samples were mixed to generate a feces pool, with
the intention of increasing the diversity of microbiota and potentially achieving a better clini-
cal response. The donors were carefully selected to include an expected natural distribution of
microbiota. We used a feces pool to minimize undetectable changes that may be present
between donors.
During the study, no adverse effects attributable to FMT-FURM were observed in patients.
However, long-term side effects cannot be discarded. In a multicenter long-term follow-up
study of FMT for recurrent CDI, 77/94 eligible patients were contacted, and 4 patients had
developed new disorders after FMT: peripheral neuropathy, Sjogren’s disease, idiopathic
Fig 3. Bar charts showing the relative abundance of OTUs at the phylum level. Distribution of bacterial
phyla in the fecal microbiota of transplantation (FMT) group and the vancomycin group (Vanco). The label of
each sample (e.g., FMT-2-0) denotes Treatment (FMT or Vancomycin), the assigned number of each patient,
and days on treatment (0 = baseline, 3 = 3 days on treatment, 7 = 7 days on treatment). To facilitate
comparison and visualization, the distribution of bacterial phyla of the donors’ pool is presented for the FMT
group (Donors’ pool). Please note that the border of the three most abundant groups was highlighted for better
visualization and the bars were organized based on the abundance of the highest abundant group (i.e.,
Firmicutes).
https://doi.org/10.1371/journal.pone.0189768.g003
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thrombocytopenic purpura, and rheumatoid arthritis [27]. On the other hand, in the same
study, some patients reported improvement in pre-existing medical conditions, such as allergic
sinusitis and arthritis. In this scenario, we intend to perform a long-term follow-up study in
our patients.
Overall, our results revealed that the microbiome in the healthy donors´ pool was different
from the microbial composition of all the patient samples, regardless of treatment, age, the
number of transplants, etc.
The average age of the donors (23.7 years) was lower than the mean age of the patients (46.7
years in vancomycin group and 39.7 years in FMT group). It is known that the intestinal
microbiome diversity differs according to age [28] and this phenomenon may have contrib-
uted to the apparent lack of FMT engraftment. We hypothesize that the use of FMT from
donors of the same age as the patients may be more likely to graft.
We would like to point out some critical observations about the composition of the fecal
microbiota in the vancomycin group as compared to the fecal microbiome of the FMT-FURM
group. In all but one case of the vancomycin group, Bacteroidetes presence was less in the last
sample (day 7) as compared to the first sample (day 0), which is in agreement with previously
published studies that have evaluated the impact of vancomycin on the gut microbiota. We
would like to highlight that there was no decrease in Bacteroidetes in the FMT-FURM group
(considering they were receiving antibiotics because of other causes).
The fact that the recipient samples did not resemble the donors’ pool was also apparent in
phyla other than Firmicutes. Despite the very low proportion of Bacteroidetes in the donors’
pool (only 3%), the levels of Bacteroidetes in the FMT-FURM group remained relatively high
and increased by day 7. Also, the proportion of Proteobacteria (mostly Enterobacteriales) was,
at all time points, greater in the FMT-FURM group than in the pooled donor sample. Further-
more, their Proteobacteria presence remained relatively stable over time. Again, these results
are intriguing since the first sample is supposed to reflect a state of dysbiosis (due to CDI), yet
Fig 4. Average bacterial composition at the phylum level. FMT: fecal microbiota transplantation.
https://doi.org/10.1371/journal.pone.0189768.g004
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Fig 5. Bar charts showing the relative abundance of OTUs at the family level. Distribution of bacterial
families in the fecal microbiota of transplantation (FMT) group and the vancomycin group (Vanco). The label
of each sample (e.g., FMT-5-0) denotes Treatment (FMT or Vancomycin), the assigned number of each
patient, and days on treatment (0 = baseline, 3 = 3 days on treatment, 7 = 7 days on treatment). To facilitate
comparison and visualization, the distribution of bacterial families of the donors’ pool is presented for the FMT
group (Donors’ pool). Please note that the border of the three most abundant groups was highlighted for better
visualization and the bars were organized based on the abundance of the highest abundant group (i.e.,
Enterobacteriaceae).
https://doi.org/10.1371/journal.pone.0189768.g005
Fig 6. Number of observed species. The figure shows the number of observed species (i.e., operational taxonomic units at 97% similarity, y-axis) and the
number of sequences per sample (x-axis) for the FMT group and Vancomycin group across collection days of fecal samples. Error bars represent standard
deviations.
https://doi.org/10.1371/journal.pone.0189768.g006
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this microbial consortium showed stability over time, a phenomenon probably supported by
the FMT. Similar to Firmicutes, Bacteroidetes and Proteobacteria did not have significant dif-
ferences in any bacterial group over time.
The microbial composition over time in the vancomycin group was different from the
microbiome in the FMT-FURM group, which seems to reflect that oral antibiotics have a pro-
found effect on the gut microbiota as has been reported before [29].
In this study, we observed an abundance of Firmicutes and Bacteroidetes on Day 3 of the
vancomycin treatment group. These bacterial groups were expected to be highly altered in
response to vancomycin therapy. Thus, the small perturbation observed in this community
may be indicative of less damage to the microbiome and may have contributed to efficacy in
this therapy group.
Apart from the fact that FMT-FURM was performed as an initial treatment for CDI, there
are two additional interesting points that distinguish our study from other standard FMT
treatments. Firstly, FMT is traditionally performed in an outpatient setting in recurrent cases
(often in patients with 3 recurrences) who have received multiple treatments for CDI and
are not currently receiving other antimicrobials. These factors profoundly influence the com-
position of the gut microbiome. Patients in the current study, however, were hospitalized at
the time of treatment and, even though they had not received treatment for CDI, they were
currently receiving or had recently received other antimicrobials for the treatment of infec-
tious diseases other than CDI. The second interesting factor is that, as mentioned above, tradi-
tional FMT is performed in a stable and controlled environment and is preceded by enteral
lavage, however, this was not performed in our study population. Given that the baseline and
modifying factors are so different between the traditional FMT patients and our population,
treatment response rates and microbiome changes should be carefully evaluated. We speculate
that the exposure to antibiotics before and/or after FMT-FURM treatment negatively influ-
enced the resolution of CDI even after re-transplantation.
It has been widely described the use of more than one infusion of FMT in the failure of
response with up to four times for recurrent or unresolved symptoms. An efficacy of 70–75%
has been observed with a single infusion, and this value increased to 85–90% when patients
were given multiple FMT infusions [30]. In our study, the value observed was 71.4%, when a
second infusion was administrated as needed. The lower value observed in our study may be
due to the concomitant use of antibiotics. We would like to emphasize that this is a pilot study
and we cannot conclude about therapeutic efficacy.
Table 5. Median (minimum-maximum) alpha diversity metrics in the FMT-FURM and vancomycin
groups.
FMT-FURM group Vancomycin group
Day 0
(n = 8)
Day 3
(n = 8)
Day 7
(n = 5)
P * Day 0
(n = 6)
Day 3
(n = 6)
Day 7
(n = 3)
P *
Number of
species
404 (346–
506)
400 (324–
503)
391 (369–
505)
0.80 408 (294–
472)
357 (295–
447)
328 (312–
382)
0.46
Shannon 4.5 (3.2–
5.7)
4.7 (2.5–
5.7)
4.7 (3.8–
5.9)
0.98 4.2 (2.5–
5.7)
3.7 (2.9–
5.1)
3.5 (3.5–
4.1)
0.77
Chao1 500 (480–
599)
464 (410–
541)
506 (464–
590)
0.08 516 (381–
567)
445 (369–
529)
452 (425–
482)
0.17
PD Whole
tree
54.1 (48.3–
61.8)
53.5 (44.2–
63.2)
51.5 (50.0–
62.4)
0.97 53.6 (46.8–
57.3)
50.6 (46.0–
56.9)
48.9 (47.7–
49.9)
0.35
* P values come from the non-parametric Kruskal-Wallis test
https://doi.org/10.1371/journal.pone.0189768.t005
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This study has several limitations a) the sample size was small. Thus the potential therapeu-
tic benefits may not be interpreted such because of larger clinical studies, with a significant sta-
tistical power, need to be done, and results may show no therapeutic value. b) the
programmed fecal samples for the microbiological examination were not obtained for all
patients. c) the primary outcome in patients was diverse, and we could not use blinding to eval-
uators for assessing primary outcome. In this study, we did not intend to define the effect of
delivery method: the treating physician decided the FMT-FURM route of administration in a
way that would not affect the patient’s care so that we do not obtain conclusions about the
delivery method of the microbiota.
In conclusion, FMT for initial CDI is associated with specific bacterial communities that do
not resemble the donors’ sample. To our knowledge, this is the first study to investigate the
effect on fecal microbiota of FMT as a first-line treatment for CDI.
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